The importance of TIGIT as a target for immune-checkpoint inhibition in lung cancer is becoming more and more clear as clinical trials continue to progress and provide results on the therapeutic effectiveness of anti-TIGIT mAbs. The gene discussed is TIGIT; the disease is lung carcinoma.